The MOA of TLX250

EP: 1.The Evolvement of Imaging in ccRCC

EP: 2.The Biggest Challenges in Distinguishing ccRCC From Benign Renal Masses

EP: 3.Strengths and Weaknesses of Imaging Modalities in ccRCC

EP: 4.Treatment or Lack of Treatment of Small Renal Masses

EP: 5.Decision-Making in Small Renal Masses

EP: 6.Current Unmet Needs in ccRCC Diagnosis

EP: 7.Early Detection of ccRCC

EP: 8.Key Benefits of PET in ccRCC Risk Stratification

EP: 9.The ZIRCON Trial

Now Viewing

EP: 10.The MOA of TLX250

The Novel Tracer 89Zr-TLX250

Main Discussion Topics:

• 89Zr-TLX250 is an antibody that binds to carbonic anhydrase IX (CAIX).
• CAIX is an enzyme expressed on the surface of most clear cell renal cell carcinomas (ccRCCs).
• The antibody is coupled to zirconium-89, a positron emitter detectable on PET imaging.

Key Points for Physicians:

• The tracer targets CAIX, which is highly expressed in ccRCC.
• The mechanism of action involves antibody binding coupled with a radioactive tracer.
• Zirconium-89 serves as the positron-emitting component for detection.

Notable Insights:

The targeting of CAIX represents a specific molecular approach to identifying ccRCC based on its unique expression pattern.

Clinical Significance:

This targeted molecular approach represents a fundamental shift from anatomic to biological characterization of renal masses.